Tools for Practice Outils pour la pratique


#136 Atypical antipsychotics for anxiety: Worth worrying about?


CLINICAL QUESTION
QUESTION CLINIQUE
Are atypical antipsychotics (alone or added to antidepressants) effective in managing anxiety disorders?


BOTTOM LINE
RÉSULTAT FINAL
Atypical antipsychotics have similar efficacy to antidepressants in generalized anxiety disorder (GAD), but are more poorly tolerated and do not improve response rates when added to antidepressants. In obsessive-compulsive disorder (OCD), approximately one in 4-8 people will have a response when antipsychotics are added to antidepressants, while one in nine will stop due to adverse effects.   



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
All included results statistically significant unless mentioned. 
  • GAD: Highest quality systematic review of nine randomized controlled trials (RCTs) (4,387 patients).1 
    • Quetiapine versus placebo (four RCTs, 2,262 patients): 
      • ResponseNumber Needed to Treat (NNT)=6. Inconsistent results. 
      • Remission: NNT=10. Inconsistent results. 
      • Withdrawal due to adverse events: Number Needed to Harm (NNH)=9. 
    • Quetiapine versus antidepressants (two RCTs, 858 patients):  
      • Similar efficacy but quetiapine more withdrawal due to adverse effects NNH=11.  
    • Quetiapine (one RCT, 22 patients)risperidone (two RCTs, 457 patients), or olanzapine (one RCT, 24 patients) versus placebo added to antidepressants:  
      • No differences except olanzapine one improved anxiety rating.  
  • OCD: Highest quality systematic review of 11 RCTs (396 patients):2 
    • Antipsychotic versus placebo added to antidepressants: 
      • Olanzapine: Not different. 
      • Quetiapine: Response NNT=8 (borderline significance p=0.07). 
        • Stopping early due to adverse effects NNH=9 over 12 weeks.  
      • Risperidone: ResponsNNT=4. 
        • No difference in stopping early for adverse effects. 
    • No RCTs versus placebo or antidepressants. 
  • Other reviews found similar results.3-10 Aripiprazole may be beneficial in OCD, based on two RCTs (79 patients).7  
  • Limitations: Short-term (≤16 weeks); all manufacturer-sponsored, often small sample sizes, unclear randomization and blinding procedures in most studies.1,2  
Context: 
  • No evidence for panic and too little evidence (two RCTs, 27 patients) for social phobia.1  
  • NNT~5-over 10-13 weeks for response from antidepressants in GAD and OCD.11,12 
  • For depression, atypical antipsychotics have stronger evidence for augmentation of antidepressants than therapy alone.13 
  • Canadian guidelines recommend atypical antipsychotics typically 3rd line (alone or adjunct) for most anxiety disorders, with risperidone and aripiprazole 1st line adjuncts in OCD.14 


Latest Tools for Practice
Derniers outils pour la pratique

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Adrienne J Lindblad BSP ACPR PharmD
  • Lisa Freeman BSc(Hon) MD CCFP

1. Depping AM, Komossa K, Kissling W, et al. Cochrane Database Syst Rev. 2010; 12:CD008120.

2. Komossa K, Depping AM, Meyer M, et al. Cochrane Database Syst Rev. 2010; 12:CD008141.

3. LaLonde CD, Van Lieshout RJ. J Clin Psychopharmacol. 2011; 31(3):326-33.

4. Maglione M, Maher AR, Hu J, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Sep. Report No.: 11-EHC087-EF.

5. Maher AR, Maglione M, Bagley S, et al. JAMA. 2011; 306(12):1359-69.

6. Dold M, Aigner M, Lanzenberger R, et al. Int J Neuropsychopharmacol. 2013; 16:557-74.

7. Veale D, Miles S, Smallcombe N, et al. BMC Psychiatry. 2014; 14(1):317. [Epub ahead of print]

8. Bloch MH, Landeros-Weisenberger A, Kelmindi B, et al. Mol Psychiatry. 2006; 11:622-32.

9. Skapinakis P, Papatheodorou T, Mavreas V. Eur Neuropsychopharmacol. 2007; 17:79-93.

10. Soomro GS. BMJ Clin Evid. 2012. pii: 1004.

11. Kapczinski FFK, Silva de Lima M, dos Santos Souza JJSS, et al. Cochrane Database Syst Rev. 2003; 2:CD003592.

12. Soomro GM, Altman DG, Rajagopal S, et al. Cochrane Database System Rev. 2008; 1:CD001765.

13. Turgeon R, Allan GM. [Publication on the Internet] Tools for Practice, Alberta College of Family Physicians. 2012 January 23. https://www.acfp.ca/wp-content/uploads/tools-for-practice/1397837410_20120123_084835.pdf. Last accessed April 9, 2015.

14. Katzman MA, Bleau P, Blier P, et al. BMC Psychiatry. 2014; 14 Suppl 1:S1.

Authors do not have any conflicts to disclose.